India’s government has capped trade margins at 30% for 137 additional cancer medicines after Supreme Court judges criticized steep price mark-ups as “extortion.” The Department of Pharmaceuticals says the new limit takes effect next month and could reduce prices by as much as 70%. The cap is expected to save patients 25 billion rupees annually. The measure extends a cap applied to 42 cancer drugs. The court cited a medicine bought by hospitals for 2,700 rupees but sold for 27,000.
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.
